Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Capital Expenditures: 2009-2025

Historic Capital Expenditures for Pediatrix Medical (MD) over the last 17 years, with Q3 2025 value amounting to $5.3 million.

  • Pediatrix Medical's Capital Expenditures fell 1513.51% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.5 million, marking a year-over-year decrease of 3104.3%. This contributed to the annual value of $22.0 million for FY2024, which is 3392.34% down from last year.
  • Pediatrix Medical's Capital Expenditures amounted to $5.3 million in Q3 2025, which was down 1513.51% from $4.5 million recorded in Q2 2025.
  • Pediatrix Medical's Capital Expenditures' 5-year high stood at $10.5 million during Q3 2021, with a 5-year trough of $3.2 million in Q4 2021.
  • In the last 5 years, Pediatrix Medical's Capital Expenditures had a median value of $7.0 million in 2024 and averaged $6.9 million.
  • As far as peak fluctuations go, Pediatrix Medical's Capital Expenditures skyrocketed by 18592.17% in 2022, and later crashed by 6196.37% in 2024.
  • Pediatrix Medical's Capital Expenditures (Quarter) stood at $3.2 million in 2021, then surged by 185.92% to $9.1 million in 2022, then dropped by 0.15% to $9.0 million in 2023, then plummeted by 61.96% to $3.4 million in 2024, then soared by 55.17% to $5.3 million in 2025.
  • Its Capital Expenditures stands at $5.3 million for Q3 2025, versus $4.5 million for Q2 2025 and $3.3 million for Q1 2025.